Zhao, Ye
Dzamko, Nicolas http://orcid.org/0000-0002-9121-0294
Article History
First Online: 3 June 2019
Compliance with Ethical Standards
:
: No funding was specifically received for the publication of this review
: ND receives funding for Parkinson’s disease research, including on LRRK2, from the National Health and Medical Research Council (NHMRC) (#1103757), the Michael J Fox Foundation for Parkinson’s disease research (MJFF), the Shake It Up Australia Foundation and the University of Sydney. In the past 12 months ND has received travel support from Denali Therapeutics, Neuropore therapies and MJFF and received payments for Grant reviews from the NHMRC and IRC. ND is a co-inventor and has received royalties from a patent on the use of LRRK2 phosphorylation sites as pharmacodynamic biomarkers (WO2011131980A1). YZ has no conflicts of interest to declare.